Elevra Lithium Ltd current report, Q3 FY2026

Elevra Lithium Ltd (ELVR) - Form 6-K Summary

Business Context and Reporting Period

This Form 6-K covers the Quarterly Activities Report for the period ended June 30, 2026, filed on July 28, 2026. Elevra Lithium Limited is North America's largest hard-rock lithium producer, operating the North American Lithium (NAL) mine in Quebec, Canada, and advancing growth projects including the Moblan and Carolina Lithium projects.

Key Financial Metrics

MetricQ4 FY26 (June 2026)Q3 FY26 (March 2026)QoQ Variance
Revenue (US$M)3181(61%)
Spodumene Sold (dmt)33,97755,526(39%)
Avg. Realised Price (US$/dmt)9211,453(37%)
Unit Operating Cost (US$/dmt)9078843%
Cash Balance (US$M)255113126%
Net Cash (US$M)20059239%
Operating Profit (NAL) (US$M)1N/AN/A
Capital Expenditure (US$M)4N/AN/A

Note: NAL reported a net operating cash outflow of US$50 million for the quarter due to working capital movements.

Material Changes vs. Prior Period

  • Revenue Decline: Revenue dropped 61% QoQ due to a 39% decrease in tonnes sold and a 37% decrease in realised price. This was driven by the finalisation of a legacy multi-year contract with a lagged pricing mechanism that did not reflect recent spot price increases.
  • Production Records: Despite lower sales, concentrate production increased 15% QoQ to 54,479 dmt, marking the second-best quarterly performance on record. A new monthly production record of 22,202 dmt was set in May 2026.
  • Operational Efficiency: Lithium recoveries improved by 5% QoQ to 71%, supported by high mill utilisation (92%) and improved feed grades.
  • Liquidity Surge: Cash balances increased significantly to US$255 million (Net Cash US$200 million) following a strategic financing package and prior to the receipt of proceeds from the Ewoyaa Project sale.

Guidance, Outlook, and Management Commentary

  • Strategic Financing: The Company secured a US$298 million package (US$196M equity placement + US$102M Convertible Notes from Canada Growth Fund) to fully fund the NAL Brownfield Expansion. The Upfront Tranche of US$46M was approved by shareholders in July 2026.
  • Expansion Milestone: Groundbreaking occurred for the fully funded NAL Expansion. An updated scoping study indicates the project will double incremental post-tax NPV to C$969 million while maintaining total capex at C$366 million.
  • Portfolio Rationalisation: Elevra agreed to sell its interest in the Ewoyaa Project (Ghana) to Huayou for approximately US$71 million cash, expected to complete in Q3 CY26. This removes future funding obligations and simplifies the portfolio.
  • Pricing Outlook: Management expects future pricing (Q1 FY27 onwards) to align more closely with spodumene spot prices now that the legacy contract is concluded.
  • Guidance: Full year FY26 results and FY27 guidance are expected in late August 2026.

Investor Verification Checklist

  • Legacy Contract Exit: Verify the exact timing of the first shipment under new spot-based pricing to confirm revenue recovery in Q1 FY27.
  • Financing Tranches: Monitor the conditions for the second tranche of the Canada Growth Fund Convertible Notes (US$56M) and shareholder approval status.
  • Ewoyaa Sale Completion: Confirm the closing date and final net proceeds of the US$71 million Ewoyaa divestment in Q3 CY26.
  • Expansion Capex: Track capital expenditure against the C$366 million budget for the NAL Expansion to ensure cost discipline.
  • Working Capital: Review the impact of inventory build-up (US$18M increase) and receivables on future cash flow statements.